Treatment of vertebrogenic pathology and radiculopathy: features of the technique of blockade (clinical lecture)
ARTICLE PDF (Українська)


pain syndromes, vertebrogenic diseases, therapeutic blockades, osteochondrosis

How to Cite

Svyrydova, N., Sereda, V., & Dovhiy, I. (2017). Treatment of vertebrogenic pathology and radiculopathy: features of the technique of blockade (clinical lecture). East European Journal of Neurology, (4(16), 2-24.


According to WHO, spinal diseases occupy fourth place after diseases of the cardiovascular system, oncological pathology and diabetes mellitus. The article presents modern information on the prevention and treatment of acute and chronic pain. The article presents modern recommendations for the appointment of funds that affect the pain syndromes, taking into account the risk factors. Also discussed the methods of blockade technique in severe pain syndromes.
ARTICLE PDF (Українська)


1. Cohen SP, Mao J. Neuropathic pain: mechanisms and their clinical implications. BMJ. 2014; 348: f7656.
2. Treede R., Rief W., Barke A., Aziz Q., Michael I. Bennett., et.el. A classification of chronic pain for ICD-11. Pain. 2015; 156(6): 1003–1007.
3. Barke A., Korwisi B., Casser H. R., Fors E. A., Geber C., Schug S. A., Stubhaug A., Ushida T., Wetterling T., Rief W., Treede R. D. Pilot field testing of the chronic pain classification for ICD-11: the results of ecological coding. BMC Public Health. 2018 Nov 7;18(1):1239.
4. Wolff D. Differential diagnostic considerations using ICD-10 in chronic back pain with special regard to persistent somatoform pain disorder with somatic and psychological factors (ICD-10 F45.41). Versicherungsmedizin. 2016 1;69(2):60-2.
5. Butler S., Landmark T., Glette M., Borchgrevink P., Woodhouse A. Chronic widespread pain-the need for a standard definition. Pain. 2016 Mar;157(3):541-3.
6. Headache Classification Committee of the International Headache Society. The international classification of headache disorders, 2nd edn. Cephalalgia 2004;24 (Suppl 1):1-160.
7. Brainin M, Barnes M, Baron JC, et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces - revised recommendations 2004. Eur J Neurol 2004;11:577-81.
8. Olesen J, Goadsby PJ, Ramadan NM, Tfelt- Hansen P, Welch KMA (eds) The Headaches, 3rd edn. Philadelphia:Lippincott, Williams & Wilkins, 2006; pp. 553-66.
9. Evers S, Kropp P, Pothmann R, Heinen F, Ebinger F. Therapie idiopathischer Kopfschmerzen im Kindes- und Jugendalter. Nervenheilkunde 2008;27:1127-37.
10. Lewis DW. Toward the definition of childhood migraine. Curr Opin Pediatr 2004;16:628-36.
11. Lewis D, Ashwal S, Hershey A, Hirtz D, Yonker M, Silberstein S, American Academy of Neurology Quality Standards Subcommittee. Practice Committee of the Child Neurology Society. Practice parameter: pharmacological treatment of migraine headache in children and adoles cents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology 2004; 63:2215-24.
12. Maytal J, Young M, Shechter A, Lipton RB. Pediatric migraine and the International Headache Society (IHS) criteria. Neurology 1997;48:602-7.
13. Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population - a prevalence study. J Clin Epidemiol 1991;44:1147-57.
14. Rasmussen BK. Epidemiology of headache. Cephalalgia 2001;21:774-7.
15. Lipton R, Scher A, Kolodner K, Liberman J, Steiner TJ, Stewart WF. Migraine in the United States:epidemiology and patterns of health care use. Neurology 2002;58:885-94.
16. Scher A, Stewart WF, Liberman J, Lipton RB. Prevalence of frequent headache in a population sample. Headache 1998;38:497-506.
17. Stovner LJ, Hagen K, Jensen R, et al. The global burden of headache:a documentation of headache prevalence and disability worldwide. Cephalalgia 2007;27:193-210.
18. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: the utility of neuroimaging in the evaluation of headache in patients with normal neurologic examinations. Neurology 1994;44:1353-4.
19. Tfelt-Hansen P, Block G, Dahlöf C, et al. Guidelines for controlled trials of drugs in migraine:second edition. Cephalalgia 2000;20:765-86.
20. Pilgrim AJ. The methods used in clinical trials of sumatriptan in migraine. Headache 1993;33:280-93.
21. Chabriat H, Joire JE, Danchot J, Grippon P, Bousser MG. Combined oral lysine acetylsalicylate and metoclopramide in the acute treatment of migraine: a multicentre double-blind placebo- controlled study. Cephalalgia 1994;14:297- 300.
22. Nebe J, Heier M, Diener HC. Low-dose ibuprofen in selfmedication of mild to moderate headache:a comparison with acetylsalicylic acid and placebo. Cephalalgia 1995;15:531-5.
23. Tfelt-Hansen P, Henry P, Mulder LJ, Scheldewaert RG, Schoenen J, Chazot G. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995;346:923-6.
24. Diener HC, Bussone G, de Liano H, et al., EMSASI Study Group. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia 2004;24:947-54.
25. Havanka-Kanniainen H. Treatment of acute migraine attack:ibuprofen and placebo compared. Headache 1989;29:507-9.
26. Kloster R, Nestvold K, Vilming ST. A double-blind study of ibuprofen versus placebo in the treatment of acute migraine attacks. Cephalalgia 1992;12:169-71.
27. Karachalios GN, Fotiadou A, Chrisikos N, Karabetsos A, Kehagioglou K. Treatment of acute  migraine attack with diclofenac sodium:a doubleblind study. Headache 1992;32:98-100.
28. Dahlof C, Bjorkman R. Diclofenac-K (50 and 100 mg) and placebo in the acute treatment of migraine. Cephalalgia 1993;13:117-23.
29. The Diclofenac-K/Sumatriptan Migraine Study Group.Acute treatment of migraine attacks:efficacy and safety of a nonsteroidal antiinflammatory drug, diclofenac potassium, in comparison to oral sumatriptan and placebo. Cephalalgia 1999;19:232-40.
30. Gobel H, Heinze A, Niederberger U, Witt T, Zumbroich V. Efficacy of phenazone in the treatment of acute migraine attacks:a double-blind, placebo-controlled, randomized study. Cephalalgia 2004;24:888-93.
31. Tulunay FC, Ergun H, Gulmez SE, et al. The efficacy and safety of dipyrone (Novalgin) tablets in the treatment of acute migraine attacks:a double-blind, cross-over, randomized, placebo-controlled, multi- center study. Funct Neurol 2004;19:197-202.
32. Myllyla VV, Havanka H, Herrala L, et al. Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine:comparable effect in a double-blind, randomized, controlled, parallel- group study. Headache 1998;38:201-7.
33. Lipton RB, Baggish JS, Stewart WF, Codispoti JR, Fu M. Efficacy and safety of acetaminophen in the treatment of migraine:results of a randomized, double-blind, placebo-controlled, population- based study. Arch Intern Med 2000;160:3486-92.
34. Lipton RB, Stewart WF, Ryan RE, Saper J, Silberstein S, Sheftell F. Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain - three double-blind, randomized, placebo-controlled trials. Arch Neurol 1998;55:210-7.
35. Diener H, Pfaffenrath V, Pageler L. The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multi-centre, randomized, double- blind, single- dose, placebo-controlled parallel group study. Cephalalgia 2005;25:776-87.
36. Goldstein J, Silberstein SD, Saper JR, Ryan RE Jr, Lipton RB. Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine:results from a multicenter, double-blind, randomized, parallel-group, single-dose, placebo- controlled study. Headache 2006;46:444-53.
37. Limmroth V, May A, Diener HC. Lysine- acetylsalicylic acid in acute migraine attacks. Eur Neurol 1999;41:88-93.
38. Bigal ME, Bordini CA, Tepper SJ, Speciali JG. Intravenous dipyrone in the acute treatment of migraine without aura and migraine with aura: a randomized, double blind, placebo controlled study. Headache 2002;42:862-71.
39. Diener HC, Eikermann A, Gessner U, et al. Efficacy of 1,000 mg effervescent acetylsalicylic acid and sumatriptan in treating associated migraine symptoms. Eur Neurol 2004;52:50-6.
40. Lampl C, Voelker M, Diener HC. Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms. J Neurol 2007;254:705-12.
41. Kudrow D, Thomas HM, Ruoff G, et al. Valdecoxib for treatment of a single, acute, moderate to severe migraine headache. Headache 2005;45:1151-62.
42. Misra UK, Jose M, Kalita J. Rofecoxib versus ibuprofen for acute treatment of migraine: a randomised placebo controlled trial. Postgrad Med J 2004;80:720-3.
43. Saper J, Dahlof C, So Y, Tfelt-Hansen P, et al. Rofecoxib in the acute treatment of migraine: a randomized controlled clinical trial. Headache 2006;46:264-75.
44. Silberstein S, Tepper S, Brandes J, et al. Randomised placebo-controlled trial of rofecoxib in the acute treatment of migraine. Neurology 2004;62:1552-7.
45. Ross-Lee LM, Eadie MJ, Heazlewood V, Bochner F, Tyrer JH. Aspirin pharmacokinetics in migraine. The effect of metoclopramide. Eur J Clin Pharmacol 1983;24:777-85.
46. Waelkens J. Dopamine blockade with domperidone: bridge between prophylactic and abortive treatment of migraine? A dose-finding study. Cephalalgia 1984;4:85-90.
47. Schulman E, Dermott K. Sumatriptan plus metoclopramide in triptan-nonresponsive migraineurs. Headache 2003;43:729-33.
48. Ellis GL, Delaney J, DeHart DA, Owens A. The efficacy of metoclopramide in the treatment of migraine headache. Ann Emerg Med 1993;22:191-5. 
49. Friedman BW, Corbo J, Lipton RB, et al. A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines. Neurology 2005;64:463-8.
50. Tfelt-Hansen P, Saxena PR, Dahlof C, et al. Ergotamine in the acute treatment of migraine. A review and European consensus. Brain 2000;123:9-18.
51. The Multinational Oral Sumatriptan Cafergot Comparative Study Group. A randomized, double- blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. Eur Neurol 1991;31:314-22.
52. Diener HC, Reches A, Pascual J, Pascual J, Pitei D, Steiner, TJ, Eletriptan and Cafergot Comparative Study Group. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine:a multicentre, randomised, double-blind, placebo-controlled comparison. Europ Neurol 2002;47:99-107.
53. Lainez MJ, Galvan J, Heras J, Vila C. Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy. Eur J Neurol 2007;14:269-75.
54. Christie S, Gobel H, Mateos V, Allen C, Vrijens F, Shivaprakash M, Rizatriptan-Ergotamine/Caffeine Preference Study Group. Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine. Eur Neurol 2003;49:20-9.
55. Evers S, Gralow I, Bauer B, et al. Sumatriptan and ergotamine overuse and drug-induced headache:a clinicoepidmiologic study. Clin Neuropharmacol 1999;22:201-6.
56. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001;358:1668-75
57. Goadsby PB, Lipton RB, Ferrai MD. Migraine: current understanding and management. N Engl J Med 2002;346:257-70.
58. The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group. A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. Eur Neurol 1992;32:177-84.
59. Geraud G, Compagnon A, Rossi A. Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomised, three-attack study. Eur Neurol 2002;47:88-98.
60. Diamond M, Hettiarachchi J, Hilliard B, Sands G.Nett R. Effectiveness of eletriptan in acute migraine:primary care for Excedrin nonresponders. Headache 2004;44:209-16.
61. Diener HC, for the ASASUMAMIG Study Group. Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double- dummy, randomized, multicenter, parallel group study. Cephalalgia 1999;19:581-8.
62. Winner P, Ricalde O, Force BL, Saper J, Margul B. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 1996;53:180-4.
63. Pascual J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache 2002;42:28-31.
64. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 2004;55:19-26.
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.